Intra Cellular Therapies | ITCI - 貿易債権者



貿易債権者 変化する 日付
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
ALKERMES USD 142.86M 40.5M 2026-06
BioCryst Pharmaceuticals USD 11.46M 501K 2026-06
Biogen USD 403.9M 45.4M 2026-06
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Cytokinetics USD 20.51M 4.2M 2026-06
Gilead Sciences USD 645M 70M 2026-03
Halozyme Therapeutics USD 23.61M 9.51M 2026-06
J&J USD 9.22B 1.24B 2026-06
Minerva Neurosciences USD 640K 305K 2025-12
Nektar Therapeutics USD 10.03M 744K 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.32B 134M 2026-03
Prothena USD 1.94M 2.36M 2026-06
RedHill Biopharma USD 731K 104K 2025-12
Supernus Pharmaceuticals USD 5.59M 4.58M 2026-06
United Therapeutics USD 497.8M 500K 2026-06
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12